Table 5.
In Vitro Antileishmanial Activity of TAs (117–124) with Modifications on Ring-A and Terminal Amine.
![]() |
survival (%) at 0.1 μMa vs |
EC50 (nM)a vs |
|||||
---|---|---|---|---|---|---|---|
compound | R1 | R2 |
L. mexicana amastigote |
J774A.1 macrophage |
L. mexicana amastigote |
J774A.1 macrophage |
TI |
117 | Et |
![]() |
0.3 ± 0.1 | 52.5 ± 16.6 | 37.1 ± 1.82 | 512 ± 0.0 | 14 |
118 |
![]() |
![]() |
−0.02 ± 0.03 | 77.3 ± 45.3 | 18.8 ± 9.70 | 450 ± 20.1 | 24 |
119 |
![]() |
![]() |
1.40 ± 0.20 | 86.6 ± 51.4 | 23.8 ± 15.9 | 717 ± 0.0 | 30 |
120 |
![]() |
![]() |
0.010 ± 0.10 | 84.6 ± 46.6 | 22.6 ± 13.9 | 946 ± 687 | 42 |
121 |
![]() |
![]() |
−0.11 ± 0.02 | 84.6 ± 47.8 | 16.2 ± 6.24 | 959 ± 0.0 | 59 |
122 |
![]() |
![]() |
−0.11 ± 0.04 | 84.8 ± 63.4 | 15.8 ± 4.38 | 547 ± 0.0 | 35 |
123 |
![]() |
![]() |
−0.05 ± 0.04 | 59.6 ± 35.6 | 11.3 ± 2.04 | > 1000 ± 0.0 | > 88 |
124 |
![]() |
![]() |
93.5 ± 26.6 | 101 ± 46 | ND | ND | ND |
miltefosine | - | - | 0.020 ± 0.010 | 39.2 ± 5.1 | 3460 ± 781 | >100000 ± 0.0 | > 29 |
Data represent the mean ± standard deviation of results of at least two independent experiments; an error of 0.0 indicates identical values were obtained for each replicate; TI = Therapeutic Index (J774A.1 EC50/L. mexicana EC50); ND, not determined. Negative values for % survival represent luminescence measurements that were somewhat below that of background and probably reflect error in measurements of very low intensities. In some instances, e.g., 117 and 119, the rank order of % survival does not correspond to that of the EC50 values. The % survival for such compounds is also very low, and the EC50 values are likely more accurate, as they entail multiple measurements over a range of concentrations and luminescence values.